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Abstract: The aim of this study was to examine the effects of weight loss induced by pharmacotherapy combined with a hypocaloric
diet for a period of 8-weeks on maximal work (Wmax) production capacity and aerobic fitness in obese patients. Twelve obese
females were put on an integrated energy restricted diet with orlistat supplement 3 x 120 mg/day. Each patient performed 3
incremental ramp exercise tests using an electromagnetically braked cycle ergometer: one at onset, one at the end of 4-weeks and
one at the end of the 8-weeks to determine Wmax production capacity. The first 4-week therapy period resulted in a significant
reduction in total body weight (91.4 ± 3.1 kg vs. 88.2 ± 2.9 kg, P = 0.0001) and body fat mass (38.7 ± 1.9 kg vs. 37.5 ± 2.0
kg, P = 0.03). However, the weight reduction achieved during first 4-weeks was not associate with increased Wmax production
capacity: 90.8 ± 5 W vs. 92.9 ± 5 W (P = 0.5). During the 8-week therapy period, further reductions in both body weight (86.0
± 2.8 kg, P = 0.0001) and body fat mass (36.2 ± 1.8 kg, P = 0.002) were observed. Wmax production capacity increased slightly
but was not statistically significant: 100.4 ± 6 W (P = 0.08). The impaired aerobic fitness of obese patients did not improve during
the short-term obesity therapy despite significant decreases in body weight and fat mass. Thus, it is important to consider an aerobic
exercise training program known to increase aerobic fitness and Wmax capacity in addition to short-term dieting and
pharmacotherapy.
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Introduction
Obesity, which describes the condition of an abnormal
accumulation of body fat mass, is directly related to
increased risk of several chronic diseases, including
glucose intolerance, hypertension, hyperlipidemia,
hemostatic variables and increased insulin resistance
(1,2). Increased positive energy due to the disrupted
energy intake and energy consumption balance (3) results
in an increased body fat mass.
A caloric restricted diet and increased physical activity
can provide a negative energy balance, which is the main
target to achieve in obesity treatment. In addition,
pharmacological agents have also been widely considered
an effective method to provide negative energy balance in
obesity treatment. It has been shown that a modest body
weight loss (in the order of 5-10% of initial body weight)

as a result of obesity treatment is generally associated
with reduced obesity related risk factors (4).
Orlistat (XenicalTM) is a pharmacological agent
promoting weight loss in obese subjects via inhibiting the
pancreatic lipase enzyme (5). The specific effects of longterm orlistat therapy on body weight and body
composition have been shown in previous studies (6,7).
However, it should be pointed out that a progressive
reduction in cardiopulmonary fitness is one of the biggest
problems in obesity (8,9). It is likely to lead serious
limitations in the ability of obese patients to perform
basic daily activities (10). There are reports suggesting
that unfit subjects have a higher risk of illness and death
compared to fit subjects with a similar body mass index
(8). That is, low levels of physical activity and decreased
physical fitness have been shown to be associated with a
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marked increase in all causes of mortality (8). In contrast,
improvement in cardiopulmonary fitness is also reported
to be associated with enhanced survival in patients with
obesity (9). Thus, the fitness of obese patients seems to
be an important protective factor against the influence of
risk factors for mortality (8). Therefore, increasing
cardiopulmonary fitness presents an important target in
addition to reducing total body weight in obesity
treatment. Thus, increased physical fitness becomes an
important part of obesity treatment in addition to
reducing body weight. In the present study, we examined
the effects of weight loss induced by orlistat therapy
combined with a hypocaloric diet on body composition,
maximal exercise performance and aerobic fitness in
obese patients.

Materials and Methods
Twelve sedentary obese females (age: 38.0 ± 2.2
years, height: 158.7 ± 1.8 cm, body mass index: 36.3 ±
1.1 kg/m2) who attended our Obesity Clinic for obesity
treatment participated in the study. All subjects had a
body mass index above 30 kg/m2. Table presents the
mean (±SE) values of the patients’ body compositions
before and after the 8-week therapy period.
Before the start of study, all subjects underwent a
pre-participation medical exam, including screening for
normal glucose tolerance, hormonal analyses (for Cushing
disease and/or hypothyroid etc.), plasma lipid profile and
ECG for cardiovascular risk assessment. Furthermore,
they were also screened for taking any medications
known to affect body composition or physical activity.
Each patient accepted the risks of the experimental
procedure explained to them and signed an informed
consent. The test procedures were approved by the
Institutional Review Board for the Use of Human Subjects
at F›rat University in Elaz›¤ in the Department of
Endocrinology and Metabolic Diseases.
Anthropometric measurements, including height and
weight, were obtained from each subject. During the
study, body weight, body mass index and body
composition were assessed at least once per week
between 0800 and 1000 hours using the leg-to-leg
bioelectrical impedance method (Tanita Body Fat
Analyser, model TBF 300), which provides an accurate
assessment of fat free mass in obese subjects and changes
in fat mass with diet (11).
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All obese patients had energy restrictions with a
hypocaloric diet coupled to drug therapy (orlistat 3 x 120
mg/day) at the optimal dosage (12). The energy content
of the diet given to the obese subjects (hypocaloric diet)
was 1200-1600 kcal/day (generally, 1400 kcal/day).
The patients were fasted overnight (no eating or
drinking) and were also requested to refrain from taking
drugs, or caffeine for a period of 12 h before the test.
After becoming familiar with the testing equipment, a
symptom limited maximal exercise test was performed by
each subject to assess cardiopulmonary and metabolic
functional capacity.
Each patient performed 3 incremental ramp tests
protocol as described by Whipp et al. (13) at a work rate
of 15 W/min using an electromagnetically braked cycle
ergometer (LODE, Groningen, The Netherlands): one on
the first day of the study, the second after 4-weeks and
the last after 8-weeks of therapy.
The exercise test protocol consists of 3 phases:
initially, the subjects started pedalling for 4 min at a
power of 20 W (60 rpm) as a warm-up period, then
incremental period where the work rate was increased 15
W/min with a work rate controller until the subjects could
no longer continue to maintain the work rate and lastly
recovery period where the cycle ergometer power was
reduced abruptly again to 20 W and the subjects
continued to cycle for 4 min.
Throughout the test, the subjects had to wear a 6lead heart rate monitor to follow ECG and heart beat. A
paired t test was used to evaluate the statistical
significance of differences between basal, 4-week and 8week values. Differences were considered significant at P
< 0.05.

Results
The individual values for the percentage changes in
body weight, fat mass, and fat free mass after 4 and 8weeks of progressive supervised therapy with hypocaloric
diet and orlistat are shown in Figure 1.
During the study, there were significant reductions in
body weight [91.4 ± 3.1 kg (basal) vs. 88.2 ± 13.5 kg
(4-weeks, -3.5%, P = 0.0001) and 86.0 ± 2.8 kg (8weeks -5.9%, P = 0.0001)] and in body fat mass [38.7
± 1.9 kg (basal) vs. 37.5 ± 1.1 kg (4-weeks, -3.1%, P =
0.03) and 36.2 ± 1.8 kg (8-weeks, -6.4%, P = 0.002)]
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(Table). In addition, fat free mass also decreased
significantly [53.0 ± 1.7 kg (basal) vs. 50.6 ± 1.1 kg (4weeks, -4.5%, P = 0.005) and 49.8 ± 1.1 kg (8-weeks,
-6.0%, P = 0.001)] (Table).

Subjects No
1

2

3

4

5

6

7

8

9

10 11 12

Body Weight Changes (%)

0
-2

Body weight reduction during the first 4-weeks of
therapy did not have a significant effect on patients’
Wmax production capacities (Table, Figure 2). The Wmax
was 90.8 ± 5 W at basal and 92.9 ± 5 W at 4-weeks (P
= 0.5). Furthermore, at the end of the 8-week period,
there was a small statistically insignificant increase in
Wmax production capacity (100.4 ± 6 W, 10.5%, P =
0.08) (Table).

-4
-6
-8

Fat Mass Change (%)

-10
6
4
2
0
-2
-4
-6
-8
-10
-12
-14
-16

During the study period, Wmax production capacity
with regard to each kilogram of body weight was 1.008
± 0.06 W/kg (basal) to 1.069 ± 0.06 W/kg (4-weeks, P
= 0.1) and 1.180 ± 0.07 W/kg (8-weeks, P = 0.01)
(Table, Figure 3).
As can be seen in Figure 4, a linear correlation
between Wmax production capacity with regard to each
kilogram of body weight and body mass index was found
[R = -0.519, (basal, P = 0.08), R = -0.723, (4-weeks, P
= 0.007); R = - 0.721, (8-weeks, P = 0.008)].

Fat Free Mass Change (%)

2
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-6
-8
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Figure 1. The changes in individual values for the total body weight, fat
mass, fat free mass in response to 4 (white column) and 8weeks (dark column) of dieting and orlistat therapy. These
values reflect the percentage of differences between basal vs.
4-week (white column) and basal vs. 8-week (dark column)
therapy periods.

Table.

It is known that a low level of physical activity can
significantly and independently contribute to obesity. As
expected, obese patients’ Wmax production was found to
be lower than that of normal subjects (14). Reduced
aerobic fitness and exercise capacity are closely related
with the level of cardiopulmonary fitness and these
findings are commonly observed in patients with a high
body mass index (15). Reduced aerobic fitness expressed
as decreased Wmax production capacity is an important

The mean (±SE) values and ranges for body mass index (BMI), body weight, fat mass (FM), fat free mass (FFM), maximal work rate
production (Wmax) and maximal work rate production capacity with regard to body weight (Wmax/BW at the onset of the study (basal)
and at the end of the 4 and 8-week therapy periods with dieting and orlistat.
Basal

BMI (kg/m2)
Weight (kg)
FM (kg)
FFM (kg)
Wmax (W)
Wmax/BW (W/kg)

36.3
91.4
38.7
53.0
90.8
1.008

±
±
±
±
±
±

1.1
3.1
1.9
1.7
5
0.06

Four-week period
(% change from the basal)
35.0
88.2
37.5
50.6
92.9
1.069

*Indicates statistically significant differences compared to basal values

±
±
±
±
±
±

1.0*
2.9*
2.0*
1.1*
5NS
0.06NS

-3.5%
-3.5%
-3.1%
-4.5%
2.3%
6.0%

Eight-week period
(% change from the basal)
34.1
86.0
36.2
49.8
100.4
1.180

±
±
±
±
±
±

0.9*
2.8 *
1.8*
1.0*
6 NS
0.07*

-6.0%
-5.9%
-6.4%
-6.0%
10.5%
17%

NS: not significant
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Figure 2. The obese patients’ maximal work production (Wmax) capacities at the onset of the study (white
column) and at the end of the 4 (grey column) and 8-week (black column) therapy periods.
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Figure 3. The mean (±SE) values for maximal work production
capacity with regard to the to the body weight (Wmax/BW)
at the onset of the study (basal), at the end of the 4-week
and 8-week therapy periods.
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A systematically reduced exercise capacity can be
linked to reduced O2 supply to the muscles during activity.
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Wmax/BW (W/kg)

1.6

factor affecting energy intake to the ratio of consumption
and leading to a positive energy balance and excess fat
mass (16,17). It has been shown that Wmax capacity
with regard to the body weight ratio can be useful in the
determination of work capacity and also aerobic fitness
when the measurement of O2 uptake is not available
(18,19). The determination of Wmax production capacity
through incremental exercise testing has been used as an
important indicator of cardiopulmonary fitness in subjects
of different fitness levels.

8-weeks

1.4
1.2
1.0
0.8
0.6
0.4

30

33
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39

BMI (kg/m2)

Figure 4. The correlation between maximal work production capacity
with regard to body weight (Wmax/BW) and body mass
index (BMI) at the onset of the study (basal), and at the end
of the 4 and 8-week therapy periods.
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An increase in type II muscle fibers and a decrease in type
I muscle fibers (20) as well as cardiovascular (21) and
pulmonary factors (22) may have an important effect on
the reduced work capacity of obese patients.
Analysis of our data showed that 4-week orlistat and
diet therapy produced a significant decrease in body
weight and fat mass reduction in our study group (23).
However, as can be seen in Figure 1, body weight loss
and fat mass reduction varied widely among the subjects.
This result shows the importance of a subject’s response
to obesity therapy consisting of dieting and orlistat.
Despite significant reductions in total body weight and fat
mass after 4-weeks of therapy, aerobic fitness as
indicated by Wmax production capacity did not increase
(24). Similarly, Wmax for each kilogram of body weight
after 4-weeks did not improve significantly.
In obesity treatment, reducing body weight without
improving aerobic fitness and work production capacity
may not benefit patients. Previous studies have shown
that weight loss results in a decrease in resting metabolic
rate and an increase in the respiratory quotient (i.e. shift
in substrate utilization from fat to carbohydrates)
(25,26). Importantly, a reduced resting metabolic rate
and an increased respiratory quotient can result in a
greater risk of body weight gain (27,28).
After 8-weeks of therapy, despite the observation of
further reductions in total body weight and fat mass,
there was no significant improvement in Wmax
production capacity (P = 0.08). Wmax for each kilogram
of body weight after 8-weeks increased more rapidly due
to reduced body size rather than increased Wmax capacity
(Figure 3). However, the increase in Wmax for each
kilogram of body weight after 8-weeks of therapy may
not benefit an obese patient’s aerobic fitness. Longer
pharmacological treatment, which may result in further
reductions in body weight, could be effective on
increasing aerobic fitness and Wmax production capacity
in obese patients.

risk of death, and small improvements in
cardiopulmonary fitness have been shown to be
associated with a significantly lowered risk of death even
in healthy people (29). Reduced cardiopulmonary fitness,
however is associated with an increased mortality rate
(30,31). Furthermore, physical activity, which is closely
related to physical fitness, has been reported to be
inversely associated with blood pressure (32), lipid
profiles (33), obesity (34) and insulin sensitivity (35).
It is well known that aerobic fitness levels play an
important role in the development of obesity because of
their significant association with physical activity. Exercise
capacity and aerobic fitness have been shown to be lower
in obese patients because of physical inactivity and
deconditioning (10). It has also been suggested that
aerobic fitness is a marker of later cardiovascular disease
with greater aerobic fitness being associated with a
reduction in the risk of later cardiovascular disease (36).
In summary, these data indicate that 8-weeks of
orlistat and diet therapy have no marked effect on obese
patients’ Wmax production capacity and aerobic fitness
despite more than 5% decrease in body weight and fat
mass. Thus, during short-term obesity therapy to
improve the impaired aerobic fitness of obese patients, it
is important to consider an aerobic exercise training
program, which is known to increase aerobic fitness and
Wmax capacity, in addition to dieting and
pharmacotherapy.
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Physical fitness provides important information on the
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